Ten Weeks After the Advisory Vote, FDA Peptide Compounding Decision Remains Pending

Research Use Only. The information on this page summarizes published peptide research for laboratory and educational reference. The compounds discussed are intended exclusively for in vitro and non-clinical research. Nothing on this page constitutes medical advice or describes human use, diagnosis, treatment, or therapeutic application.

Overview

On July 23 and 24, 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of seven nominated peptides for the Section 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax. Only emideltide failed. More than ten weeks later, the FDA has not acted on the recommendation, and the vote remains what it was on the day it happened: advice the agency is free to accept, modify, or set aside.

For the vote itself, see the earlier GENEVIUM coverage: FDA Panel Recommends Six of Seven Peptides for Compounding. This update covers what has and has not moved since.

What the Vote Did and Did Not Do

The PCAC vote is one step in a three-step process that is often reported as a single event. A peptide must first come off the Category 2 list of substances with safety concerns. The advisory committee then makes its recommendation. Only after that does the FDA place a substance on the bulks list, through notice-and-comment rulemaking. Legal analysts estimate that the final step commonly takes eight to twelve months before 503A pharmacies have clear legal authority to compound.

The margins were narrow. BPC-157, KPV, and TB-500 each passed 8 to 6 with one abstention. MOTS-c passed 7 to 5 with two abstentions. None of the votes constitutes FDA approval, and none establishes clinical benefit. Bulks list placement would only allow licensed pharmacies to prepare these substances for individual patients with a prescription.

How the Pathway Got Here

In September 2023, the FDA placed BPC-157, TB-500, and 17 other peptides in Category 2, citing safety concerns. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that roughly 14 of those 19 would move toward compounding eligibility. By April 2026, BPC-157 and ipamorelin had been formally removed from Category 2.

The July vote went against the unanimous position of FDA scientific staff, who reported an absence of human clinical data for four of the seven nominees. Staff also raised a more basic problem: several of these compounds lack a universally accepted chemical definition, which makes them difficult to evaluate at all.

Questions About the Panel

Eight of the 14 voting members were recent appointees. Reuters reported that six of the new appointees operate or work for clinics that offer peptide treatments. HHS stated that every member completed the standard FDA ethics review. The composition has become part of the debate over how much weight the recommendation should carry.

States Are Not Waiting

Day-to-day compounding oversight sits with state pharmacy boards, and the states are splitting. Connecticut, Alabama, New York, California, Massachusetts, and Louisiana have moved to restrict peptide compounding. Texas, Florida, Nevada, and Arizona remain permissive. More than 40 state attorneys general have sent coordinated letters to the FDA raising safety concerns.

The result is a patchwork. A compounded peptide permitted in one state may be restricted in the next, regardless of what happens at the federal level.

Rulemaking Slow, Enforcement Active

Trade press coverage in late September described the two FDA tracks moving at different speeds: rulemaking on the compounding pathway has stalled, while the enforcement side of the agency continues to act against sellers. The agency has also shown that it will close a pathway when it chooses to, through its April 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. See FDA Ban on Compounded Semaglutide and Tirzepatide.

What This Means for Research Buyers

The compounding pathway governs what pharmacies may dispense to patients. It does not change sourcing requirements or documentation standards for Research Use Only material, and nothing in the ten weeks since the vote has changed that.

What the debate has done is put quality in the spotlight. Reporting this fall cited systematic analyses finding that unregulated peptide products contained between 5% and 75% of their labeled content, along with Class 1 impurities including arsenic. For a laboratory, a mislabeled or contaminated reference material invalidates the experiment it goes into.

That is why the line between legitimate research peptide commerce and gray-market distribution is analytical verification, not the molecules sold. Third-party HPLC Purity Testing, mass spectrometry identity confirmation, and batch-specific certificates of analysis are the standard, not a feature. GENEVIUM supplies BPC-157 and TB-500 for research use only, with batch-specific COA documentation on every order.

GENEVIUM will update this coverage when the FDA publishes a proposed rule or otherwise acts on the PCAC recommendations.

References